Ab0876 impact of autoantibody profile on future organ involvement in systemic sclerosis: disease free survival in different patient groups

Background Some specific autoantibodies were known to be associated with cutaneous subtype, type of organ involvement and prognosis in systemic sclerosis (SSc). Objectives The aim of our study was to evaluate the impact of autoantibody profile on the course of SSc regarding new organ involvement over time. Methods The data of 206 consequitive patients (189 women) with SSc who were followed up at least 12 months were retrospectively analyzed. Associations between the autoantibodies (anti-nuclear antibody (ANA) (27.7%, n=57), anti-Scl70 (47.1%, n=97) and anti-centromere (ACA) (22.3%, n=46)) and disease-free survival (without new organ involvement) were evaluated in SSc patients with a mean follow-up time of 101.26±71.02 months. Results Anti-Scl70 was associated with diffuse cutaneous disease involvement, digital ulcers, arrhythmia, and interstitial lung disease (ILD) (OR:3.43, p<0.001, OR:1.835, p=0.033, OR:4.06, p=0.038 and OR:2.393, p=0.006, respectively). ACA was associated with PAH (OR:3.319, p=0.040) and protective against diffuse skin involvement, flexion contractures and ILD (OR:0.203, p=0.001, OR:0.251, p=0.012 and OR:0.288, p=0.008, respectively). In ACA (+) group, new organ involvement was observed less frequently (HR: 0.523 (95% CI (0.29-0.94), p=0.030) and after a longer time period when compred to ACA (-) group (82.65±14.5 vs 53.98±5.49 months, p=0.026). At the 5th and 8th years of the follow-up, half of the ACA(+) patients did not develop new organ involvement. In the ACA(-)[(ANA(+) or antiScl70(+)] group, new organ involvement was detected in >67% within 5 years and in >80% within 8 years (figure-1, table-1). Conclusion Although ACA(+) patients are considered to have a better prognosis, some patients may develop new or worsening manifestations after a longer time period. The prognosis of ANA or anti-Scl70(+) patients was shown to be more severe and most patients had new organ involvement within the first 5 years of the disease, warranting a careful evaluation and efficacious treatment at this period. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.